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Antigen specificity of anti-nuclear antibodies 
complexed to nucleosomes determines glomerular 
basement membrane binding in vivo
Monoclonal anti-nuclear antibodies which are complexed to nucleosomes are 
able to bind to the glomerular basement membrane (GBM) in vivo, whereas 
purified antibodies do not bind. The positively charged histone moieties in the 
nucleosome are responsible for the binding to anionic determinants in the 
GBM. We tested the hypothesis that the specificity of the autoantibodies com­
plexed to the nucleosome influences the glomerular binding of the antibody- 
nucleosome complex. We induced the formation of these immune complexes in 
vivo, by intraperitoneal inoculation of hybridomas producing monoclonal anti- 
nuclear antibodies (four anti-histone, three anti-double stranded (ds)DNA and 
three anti-nucleosome antibodies) into nude BALB/c mice. In ascites and 
plasma from the mice inoculated with these hybridomas, nucleosome/autoanti- 
body complexes were detected in comparable amounts. Immunofluorescence of 
kidney sections revealed that about 60% of the mice inoculated with anti- 
nucleosome or anti-dsDNA hybridomas had immunoglobulin deposits in the 
GBM, whereas only 15% of the mice with anti-histone hybridomas showed 
these deposits (p <  0.04). In the Matrigel®-ELISA (used as a GBM surrogate) 
ascites from anti-nucleosome or anti-DNA hybridomas displayed significantly 
higher titers (p <  0.002) than ascites from anti-histone hybridomas. In conclu­
sion, nucleosome/immunoglobulin complexes comprising anti-nucleosome or 
anti-dsDNA auto-antibodies do bind more frequently to the GBM in vivo than 
nucleosome/immunoglobulin complexes containing anti-histone antibodies. It 
therefore appears that the specificity of the antibody bound to the nucleosome is 
a critical determinant for the nephritogenic potential of the nucleosome- 
autoantibody complex.
1 Introduction
Systemic lupus erythematosus (SLE) is a disease charac­
terized by the presence of autoantibodies which react with 
nuclear antigens [1, 2]. In recent years it has become clear 
that the nucleosome is an important auto-antigen in SLE 
[3, 4]. Nucleosomes are not only important in the induc­
tion phase of lupus but also for the evolution of tissue 
lesions, especially glomerulonephritis. The observation 
that DNA circulates in SLE patients in the form of oligo- 
nucleosomes [5, 6] and that nucleosome-specific antibo­
dies are formed in the majority of SLE patients [7-9] sug­
gested that formation of nucleosome anti-nucleosome 
complexes might be an alternative explanation for the 
pathogenesis of lupus nephritis. Indeed, recently nucleo­
somes were identified for the first time in GBM deposits in 
human lupus nephritis [10]. In renal perfusion studies we 
could show that nucleosome/autoantibody complexes bind
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to the GBM via an interaction of cationic histone moieties 
within the nucleosome to anionic heparan sulfate (HS) [11, 
12]. From these renal perfusion experiments we also 
learned that a relative decrease of DNA or a relative 
increase in histone content within the nucleosome could 
increase the capacity of the nucleosome/autoantibody 
complex to bind to HS in the GBM [12]. The presence of 
the N-terminal regions of the core histones carrying many 
positive charges seems to be a critical determinant for this 
binding since masking of these positive charges by heparin 
completely prevents GBM binding [13]. These N-terminal 
regions harbor the epitopes for histone-specific autoanti­
bodies [14, 15]. We reasoned that binding of anti-histone 
antibodies to these N-terminal regions would decrease the 
capacity of the nucleosome-antibody complex to bind to 
the GBM, whereas DNA and nucleosome-specific autoan­
tibodies would relatively spare these N-terminal regions. 
Therefore, we compared the glomerular binding of differ­
ent nucleosome-, histone- and dsDNA-specific mono­
clonal antibodies complexed to nucleosomes after intrape­
ritoneal inoculation in nude BALB/c mice. Thise pro­
cedure will induce nucleosome/Ig complex formation in 
vivo [16]. In purified non-complexed form, none of the 
tested antibodies binds to the GBM in vivo as assessed by 
renal perfusion studies.
2 Materials and methods
2.1 Animals
BALB/c nu/nu mice and Wistar rats were bred in the ani­
mal facilities of the University of Nijmegen.
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2.2 Renal perfusion of purified anti-nuclear antibodies
Anti-nudc.'S' > ’ Ï«. Ì t.i ■ui sr v t iü c ü v  ::!<íh:;t ;:¡,¡; h;:;,:-
2.6 Ànti-inatrigel ELISA
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salt conditions preceded by a DNase treatment -
performed as described previously [11, 12].
Wistar
xtracted from the
mouse Englebreth-Holm-Swarm (LHS) tumor, consisting 
ot laminin, entactin, collagen IV and heparan sulfate pro­
teoglycan. was used as a "GBM surrogate". Matrigel was 
first treated with DNase (DNase grade II, Boehnnger) to 
remove DNA contamination and was coated to Greiner 
plates (Greiner. Frickenhausen, Germany) at 1 |ig in 100 ul 
PBS per well overnight at room temperature. After wash-
Tüü „ . , . . . . ing the plates five times with PBS containing 0.1% Tween-
EF was carried out in a Phast system separation unit (pH 20, plates were blocked with 10 mM Tris-HCl pH 7.4 con-
range of the gels 3-9) according to the manufacturer’s taining5% (wt/vol) bovine serum albumin (BSA|. 15(1 ul/ 
instructions (Pharmacia, LKB, Uppsala, Sweden). - -
2.3 Isoelectric focussing (IEF) of purified anti-nuclear
antibodies
2.4 Inoculation with anti-nuclear hybridomas in nude 
BALB/c mice
well, for 1 h at 37°C. Next, samples were diluted in PBS
containing 1 % (wt/vol) BSA, 100 ul per well for 1 h at
37°C. Plates were washed again five times and incubated
with peroxidase-labeled rat anti-mouse mAh Ig (CLB-
RM-19, CLB, Amsterdam, The Netherlands) diluted 1/
1000 in 100 ¡.d PBS/well. Further procedures were identical 
From a panel of hybridomas producing monoclonal anti- to the anti-nuclear ELISA as described [12]. Purified anti-
nuclear antibodies, four anti-histone, three anti-dsDNA dsDNA, anti-histone and anti-nucleosome antibodies did
and three nucleosome-specific hybridomas were selected, not bind to DNase-treated Matrigel, whereas antibodies
mAb 2, 32 and 34 are anti-nucleosome-specific hybrid- specific for laminin, entactin, collagen IV. HS-glyeo-
omas directed against H2A-H2B/DNA (mAb 2 and 32) or saminoglycan (GAG) or HSPG core protein showed high
H3-H4/DNA (mAb 34) [17] mAb 2 was obtained by fusion reactivity (data not shown), 
of spleen cells from a graft-versus-host mouse and mAb 32
and 34 from NZB/W mice. mAb 36, 53 and 56 are anti-
dsDNA hybridomas obtained from NZB/W mice [18]. 2.7 Nucleosome/IgG complex assay 
mAb KM2, LG2-1, LG2-2 and MRA12 are anti-histone
hybridomas originating from MRL/lpr mice. The anti- The nucleosome/IgG complex assay was performed as pre-
histone hybridomas KM2, LG2-1 and LG2-2 are directed viously described [16]. Briefly, Protein A/G (Pharmaciu)-
against determinants located in the basic N-terminal coated plates were incubated with plasma or ascites sam-
domain of the core histones (KM2 recognizes aa 1-20 of pies (diluted 1/20 or 1/250 respectively). After three
H2A and aa 1-29 of H4, LG2-1 recognizes aa 30-45 of H3 washes, nucleosome/IgG complexes were identified using
and LG2-2 recognizes aa 1-13 of H2B) [14]. MRA12 recog- DNA-specific probes (biotinylated nucleotides). In addi-
nizes a conformational determinant of the HI molecule tion the nucleosome/IgG complex assay was performed
requiring both the globular and C-terminal domains [19, using biotinylated anti-histone mAb KM2 instead of the
20]. All mAb are IgG2a except for mAb 2 and 53 which are biotinylated nucleotides, allowing identification of the
IgG2b. An IgG2a anti-human CD7 monoclonal (WT1) nucleosome/IgG complexes via their histone part. Ascites
samples were diluted 1/20 instead of 1/250 since the assay 
using biotinylated anti-histone mAb was less sensitive than
Seven-week-old BALB/c nu/nu mice received 0.5 ml sterile the assay using biotinylated nucleotides. Samples contain-
pristane (4,6,10,14-tetramethylpentadecane; Sigma, Poole, ing only free (non-complexed) nucleosomes, histones and/
-  y >  \  >  .  t  j «  i  •  < 4 4
served as control.
or DNA were negative in both assays.GB) 10 days prior to intraperitoneal (i. p.) injection of 3 x 
106 hybridoma cells. As controls, six mice received hybrid- 
oma cells secreting anti-human CD7 and four mice pristane
alone. When mice developed visible tumor growth and/or 2.8 Characterization of DNA in plasma and ascites 
ascites, ascites and plasma were collected for determination
of antibody levels, anti-nuclear reactivity and the amount of DNA was extracted from plasma and ascites using phenol
nucleosome/Ig complexes. Albuminuria was screened with saturated with 0.1 MTris (pH 8). For DNA quantification,
Albustix (Boehringer Mannheim, Germany). Only those a DNA assay, was performed [16,21]. DNA concentrations
animals that developed both visible ascites (and tumors) were determined by reference to standard curves con-
and anti-nuclear antibody reactivity were subjected to fur- structed from pBR 322 DNA. Electrophoresis of DNA was
ther examination. Although the time required to develop carried out in 1.5 % agarose gels in 40 mMTns-acetate buf-
ascites varied (albeit unsignificantly), mice were always kil- fer pH 8 containing 1 mM EDTA. Gels were stained with
^  »  « «  ■« • .  it  _ 1 .  ______ L _  __ -  ^  ^  /  1 I  I \
led 3 to 5 days after the onset of visible ascites. ethidium bromide (1 [¿g/ml).
2.5 Determination of immunoglobulin concentration and 2.9 Characterization of nucleosome/Ig complexes
antibody reactivities in ascites and plasma . .
For identification of DNA and histones in the nucleosome/
The immunoglobulin (Ig) concentrations and the anti- Ig complexes, plasma/ascites samples were mixed with 
histone, anti-dsDNA and anti-nucleosome reactivites were protein A-Sepharose beads (Pharmacia, Uppsala Swe-
assessed by ELISA, as described previously [12]. den) for 30 min. After centrifugation, the beads were
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Table I. immunofluorescence findings in kidney sections of mice inoculated with the anti-DNA (nos. 56, 36 and 53), anti-histone 
(KM2, LG2- 1 and LG2-2), anti-nucleosome (nos. 32, 34 and 2) or control (anti-CD7) hybridomas. Incidence of positive staining 
(score >  1 ) on immunofluorescence
Hybridomas GBM deposits Mesangial deposits Nuclear staining
Anti-CD7 0/6a) 3/6 0/6
Anti-histone 2/I3h) 9/13 9/13
Anti-dsDNA 9/15 14/15 10/15
Anti-nucleosome 8/13 8/13 12/13
a) Number of mice with positive staining/total number of mice
b) Anti-histone v.v. anti-nucleosome hybridomas (p = 0.04); anti-histone vs. anti-dsDNA hybridomas (p — 0.02)
2B, lanes 3 -5 ). No DNA was isolated from beads incu­
bated with control ascites (Fig. 2B, lane 2), SDS-PAGE 
electrophoresis of the material eluted from the protein A  
Sepharose beads revealed the presence of Ig heavy and 
light chains and the four core histones, while HI was not 
detectable. Only Ig heavy and light chains were found on 
protein A  beads incubated with control ascites or MRA12 
ascites (data riot shown).
Matrigel reactivity in ascites of mice inoculated with the 
different hybridomas correlated with the in vivo GBM  
binding (Rs =  0.63; p  <  0.0001). Furthermore, Matrigel 
reactivity in ascites containing anti-DNA or anti- 
nucleosome antibodies correlated significantly (Rs = 0.51; 
p  =  0.005) with the amount of nucleosome/Ig complexes in 
the ascites in contrast to the ascites containing anti-histone 
antibodies.
3.5 Glomerular deposition
The kidneys of the mice with nucleosome/Ig complexes in 
their ascites/plasma (ƒ. e. all mice except those inoculated 
with the anti-Hl hybridoma MRA12) and of mice inocu­
lated with the control hybridoma were examined by direct 
IF for Ig deposition. Different staining patterns were 
observed. Deposits along the glomerular capillary wall were 
observed in 8/13 mice that received anti-nucleosome and in 
9/15 mice that received anti-DNA hybridomas. In contrast, 
only 2/13 mice that received anti-histone hybridomas had 
GBM-Ig deposits, which was significantly different (p <
0.04). In mice that received anti-human CD7 hybridoma or 
pristane alone no deposits along the capillary walls and only 
scant mesangial deposits of IgG2a were observed (Fig. 3A). 
An increased incidence and severity of deposits were 
observed in the mesangium of mice that received anti- 
nuclear hybridomas, as compared to the anti-CD7 bearing 
control (Table 1). Nuclear staining was observed in 9/13 
mice injected with the anti-histone hybridomas (Fig. 3C), in 
10/15 mice bearing anti-dsDNA and in 12/13 mice carrying 
anti-nucleosome hybridomas (Table 1). The nuclear stain­
ing was always observed in mice with positive GBM-Ig 
deposits (Fig. 3D) except for mAb 53 (Fig. 3B),
The pathogenic potential of the bound nucleosome/Ig 
complexes can be derived from the observation that C3 
deposition was seen in some (16%) of the mice with com­
plex deposition. Furthermore, mild proteinuria (300 mg/ 
ml) developed only in mice inoculated with the anti-DNA  
(2/15) or anti-nucleosome (3/13) hybridomas.
3.6 Binding to extra cellular matrix (Matrigel-ELISA)
In a Matrigel-ELISA (used as a GBM surrogate), ascites 
of mice inoculated with anti-nucleosome or anti-DNA  
hybridomas displayed significantly higher titers than asci­
tes of mice inoculated with anti-histone hybridomas 
(median titers: 20 and 60 versus 2; p  values <  0.002). The
4 Discussion
Large amounts of nucleosomes are released from cells 
undergoing apoptosis in hybridoma cell cultures [23] and 
in ascites from mice inoculated intraperitoneally with 
hybridomas [16]. If this release occurs in the presence of 
anti-nuclear antibodies one can envision that nucleosome- 
autoantibody complexes are formed, as recently described 
for anti-DNA hybridomas [16]. Our study confirms and 
extends these observations since in ascites of mice inocu­
lated with anti-histone or anti-nucleosome hybridomas, 
nucleosome/Ig complexes are also present. The D N A  in 
these complexes has characteristics of nucleosomal DNA  
released by apoptosis [5, 6 ]. Within the nucleosome/Ig 
complexes the four core histones are also present, but no 
HI, confirming previous observations in bovine serum [24] 
and hybridoma supernatants [12, 23].
The amount of nucleosome/Ig complexes, found in ascites 
or plasma, was equal and not influenced by the anti- 
nuclear specificity of the hybridoma product with the 
exception of anti-Hl. In control mice inoculated with the 
anti-CD7 hybridoma an identical amount of nucleosomes 
was found, but no nucleosome/Ig complexes, excluding 
nonspecific generation of these complexes. Despite the 
fact that the amount of nucleosome/Ig complexes was not 
significantly different among mice inoculated with the var­
ious anti-nuclear specificities, we observed clear differ­
ences in the glomerular localization of these complexes: 
high for anti-DNA and anti-nucleosome, low for anti- 
histone hybridomas. This is in line with the suggestion that 
anti-histone auto-antibodies are less nephritogenic in 
lupus [25-28] than anti-DNA [29] or anti-nucleosome anti­
bodies [8 , 30], We also found that the amount of anti- 
histone antibodies deposited in glomeruli was similar in 
age-matched albuminuric and non-albuminuric MRL/1 
lupus mice in contrast to anti-nucleosome and anti-DNA  
reactivities which were increased in albuminuric animals
[31]-
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There was a correlation between the in vivo GBM binding 
and the in vitro Matrigel reactivity in ascites. The observed 
Matrigel reactivity and in vivo GBM-binding of these 
autoantibodies is due to complexation to nucleosomes 
since these same antibodies in purified non-complexed 
form bound neither to Matrigel nor to the GBM in vivo.
The methodologies exploited in this study have also been 
used by others to evaluate glomerular immune deposit 
formation of murine [32-34] or human [35] anti-DNA anti­
bodies. In these studies, the antibody deposition in mesan- 
gium and GBM varied for the different antibodies used. 
Based on these observations, it was postulated that direct 
binding of anti-DNA antibodies to intrinsic glomerular 
antigens is the major mechanism for this immune deposit 
formation. However, for some of the mAb described, the 
formation of GBM deposits was only observed after i.p. 
hybridoma inoculation and not after i.v. injection of puri­
fied mAb [33, 35], which suggests that this glomerular 
binding is due to complex formation with nucleosomes [1 1 ,
16, 36].
In many of the mice inoculated with anti-nuclear hybri- 
domas, nuclear localization of autoantibodies (in vivo 
A N A ) was observed in the different tissue specimens. 
Recently, it was reported that this in vivo ANA is a feature 
of anti-nuclear antibodies complexed to nucleosomes since 
binding to the cell surface and transport into the cytoplasm 
only occurred if the antibodies were complexed to nucleo­
somes [37, 38]. The observed nuclear localization of our 
mAb was a fixation artifact, since if we used a paraformal­
dehyde fixation, instead of acetone, this nuclear staining 
did not occur [38].
In conclusion, this study shows that complexes formed 
between nucleosomes and anti-DNA or anti-nucleosome 
autoantibodies more frequently localize in the GBM than 
those formed between nucleosomes and anti-histone anti­
bodies. In our view, this latter is due to the fact that these 
anti-histone antibodies bind to the positively charged N- 
terminal regions of the core histones. This reduces the 
capacity of these histone moieties to bind to HS-associated 
anionic sites within the GBM.
This study was supported by a grant from  the Dutch Kidney
Foundation (C95.1513).
5 References
1 Tan, E. M ., Adv. Im m unol  1989. 44: 93,
2 Hardin, J. A ., Arthritis Rheum. 1986. 29: 457.
3 Tax, W. J. M., Kramers, C., van Bruggen, M. C. J. and Ber- 
den, J. H. M., Kidney Int. 1995. 48: 666.
4 Mohan, C. and Datta, S. K., Clin. Immunol. Immunopathol.
1995. 77: 209.
5 Fournie, G. J., Kidney Int. 1988. 33: 487.
6 Rum ore, P. M. and Steinman, C. R., J. Clin. Invest. 1990. 86:
69.
7 Chabre, H ., Amoura, Z., Piette, J. C., Godeau, P., Bach, J. F. 
and Koutouzov, S., Arthritis Rheum. 1995. 38: 1485.
8 Burlingame, R. W., Boey, M. L., Starkebaum, G. and Rubin,
R. L., J. Clin. Invest. 1994. 94: 184.
9 Massa, M., dc Benedetti, F., Pignatti, P., Albani, S., Di Fuc- 
cia, G., Monestier, M. and Martini, A ., Clin. Exp. Rheumatol
1994. 32: 219.
10 van Bruggen. M. C. J., Kramer*. Wdlurcui. i l .  I-Juïm. 
•I. D.. Kallenberg. C. G. M.. van den Born. L .  Smeenk, 
R. J. T . Assmann. K. J. M.. Muller. S.. Monestier. M 
and Berden, J. 1L M.. Nephrol D ial Transplant. IW . 12: 57.
11 Termaat, R. M., Assmann, K. J. M., Dijkman. H. B. 1' M.,
Smeenk, R. J.T. and Berden, J. fl. M.. Kidne\ Int. 1992. 42; 
1363.
12 Kramers, C.. Hylkema. M. N.. van Bruggen, M. C. J.. van de 
Lagemaat. R., Dijkman. H. B. P. M., Assmann. K. L M.. 
Smeenk, R. J.T. and Berden, J. IL M.. L Clin. Invest. IW . 
94: 568.
13 van Bruggen, M. C. J., Walgreen, IL, Rijke. Ci. V. M.. Cor 
sius, M., Hylkema. M. N., Assmann, K, ,J. M., van Dedem, 
G., Smeenk, R. J. T. and Berden. J. H. M., Kidnev Int. 1996. 
II: 1219.
14 Monestier, M., Fasy.T. M., Losman. M. J.. Novick, K. li. and 
Muller, S., M o l Immunol 1993. 30: 1069.
15 Muller, S. and van RegenmorteL M. H. V.. in Van Regen inor­
te 1, M. H . V. (Ed.), Structure o f  antigenv, GRC Press. B<>ca
Raton 1993, p. 149.
16 Fournié, G. J., Clin. Exp. Immunol 19%. ¡04: 236,
17 Kramers, C., Stemmer, C., Monestier, M., van Bruggen. 
M. C. J., Rijke,T., Hylkema, M. N., Smeenk, R. J. L. Muller.
S. and Berden, J. H. M., 1. Autoimmun. 1996. 9: 723.
18 Smeenk, R. J. T., Brinkman, K., Van den Brink. H. G. and 
Westgeest, A. A. A., I . Immunol 1988. 140: 3786.
19 Monestier, M., Eur. J. Immunol 1991, 21: 1725.
20 Monestier, M., Fasy. T. M. and Böhm. L., M ol Immunol 
1989. 26: 748.
21 Le Lunn, A. D., Fournié, G. J., Boissier, L.,Toutuin, P. L. 
and Benoisi, H., Cancer Immunol bnmunother. 1994. 104: 
241.
22 van Bruggen, M, C. J., Kramers, C., Hylkema. M. N., van 
den Born, J., Bakker, M. A. H., Assmann, K. J. M., Smeenk, 
R, J. T. and Berden. J. H. M., Am. 1. Pathol 1995. 146: 753.
23 Franek, F. and Dolnikova, J., FEBS 1991. 284: 285.
24 Waga, S.,Tan, E. M. and Rubin, R. L., Biochem. 1. 1987. 244: 
675.
25 Epstein, A ., Greenberg, M., Halbert, S., Kramer, L. and Bar­
land, P., J. Rheumatol. 1986. 13: 304.
26 Cohen, M. G., Pollard, K. M. and Webb, J., Ann. Rheum. 
Dis, 1992. 51: 61.
27 Fritzler, M., Ryan, P. and Kinsella,T. D., J. Rheumatol 1982. 
9: 46,
28 Muller, S., Barakat, S., Watts, R., Joubaud, P. and Isenberg, 
D., Clin. Exp. Rheumatol 1990. 8: 445.
29 ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C. and 
Kallenberg, C. G. M., Arthritis Rheum. 1990. 33: 634.
30 Suenaga, R. and Abdou, N. I., J. Rheumatol. 1996. 279.
31 van Bruggen, M. C. J., Kramers, C., Hylkema, M. N., 
Smeenk, R. J. T. and Berden, J. H. M., Clin. Exp. Immunol
1996. 105: 132.
32 Foster, M. H., Cizman, B. and Madaio, M. P., Lab. Invest. 
1993. 69: 494.
33 Vlahakos, D. V., Foster, M. H., Adams, S., Katz, M., Ucci, 
A. A ., Barrett, K. J., Datta, S. K. and Madaio, M. P., Kidney
Int. 1992. 41: 1690.
34 D ’Adrea, D. M., Coupaye-Gerard, B., Kleyman, T. R., Fos­
ter, M. H. and Madaio, M. P., Kidney Int. 1996. 49: 1214.
35 Ehrenstein, M. R., Katz, D. R., Griffith, M. H., Papadaki, 
L., Winkler, T. H., Kalden, J. R. and Isenberg, D. A ., Kidney
Int. 1995. 48: 705.
36 Morioka,T., Fujigaki, Y., Batsford, S. R., Woitas, R., Oite,T., 
Shimizu, F. and Vogt, A., Clin. Exp. Immunol 1996.104: 92.
37 Koutouzov, S., Cabrespines, A., Amoura, Z., Chabre, H., 
Lotton, C. and Bach, J. F., Eur. I. Immunol 1996, 26: A ll .
38 Kramers, C., van Bruggen, M. C. J., Rijke-Schilder, G. P. M., 
Dijkman, H. B. P. M., Hylkema, M. N., Croes, H. J. E., Fran­
sen, J. A. M., Assmann, K. J. M., Tax, W. J. M., Smeenk, R. 
J. T. and Berden, J. H. M., / .  Am. Soc. Nephrol 1996. 7; 946.
